Dual functional monoclonal antibody PF-04605412 targets integrin α5β1 and elicits potent antibody-dependent cellular cytotoxicity

Cancer Research

Volumn 70, Issue 24, 2010, Pages 10243-10254

  Li, Gang ^a   Zhang, Lianglin ^a   Chen, Enhong ^a   Wang, Jianying ^a   Jiang, Xin ^a,b   Chen, Jeffrey H ^a   Wickman, Grant ^a,c   Amundson, Karin ^a,d   Bergqvist, Simon ^a   Zobel, James ^a   Buckman, Dana ^a   Baxi, Sangita M ^a   Bender, Steven L ^a   Casperson, Gerald F ^a   Hu Lowe, Dana D ^a  

^a PFIZER INC   (United States)

^b Sova Pharmaceuticals   (United States)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d Tocagen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CASPASE 3; CD16 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; PF 0337210; PF 04605412; PF 5412; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VOLOCIXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; HAPLORHINI; HUMAN; HUMAN CELL; HYBRIDOMA; IN VITRO STUDY; LUNG METASTASIS; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; WILD TYPE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ENDOTHELIAL CELLS; HAPLORHINI; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INDOLES; INTEGRIN ALPHA5BETA1; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; NIH 3T3 CELLS; PHAGOCYTOSIS; PYRROLES; RECEPTORS, IGG;

EID: 78650371664     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1996     Document Type: Article

References (50)

1. Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D, et al. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 2002;22:927-33.
2. Muschler JL, Horwitz AF. Down-regulation of the chicken alpha 5 beta 1 integrin fibronectin receptor during development. Development 1991;113:327-37.
3. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006;312:651-8.
4. Magnussen A, Kasman IM, Norberg S, Baluk P, Murray R, McDonald DM. Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 2005;65:2712-21.
5. Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. J Cell Sci 1999;112:569-78.
6. Takagi J, Strokovich K, Springer TA, Walz T. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J 2003;22:4607-15.
7. Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem 1999;74:135-43.
8. Korah R, Boots M, Wieder R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004;64:4514-22. (Pubitemid 38856923)
9. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90:561-5.
10. Edward M. Integrins and other adhesion molecules involved in melanocytic tumor progression. Curr Opin Oncol 1995;7:185-91.
11. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 2008;68:2329-39.
12. Shinohara M, Nakamura S, Sasaki M, Kurahara S, Ikebe T, Harada T, et al. Expression of integrins in squamous cell carcinoma of the oral cavity. Correlations with tumor invasion and metastasis. Am J Clin Pathol 1999;111:75-88. (Pubitemid 29024969)
13. Blase L, Daniel PT, Koretz K, Schwartz-Albiez R, Moller P. The capacity of human malignant B-lymphocytes to disseminate in SCID mice is correlated with functional expression of the fibronectin receptor alpha 5 beta 1 (CD49e/CD29). Int J Cancer 1995;60:860-6.
14. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000;6:96-101.
15. Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 2008;26:7-12.
16. Kuwada SK. Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr Opin Mol Ther 2007;9:92-8.
17. Griggs J, Zinkewich-Peotti K. The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer 2009;101:1807-12.
18. Becknell B, Caligiuri MA. Natural killer cells in innate immunity and cancer. J Immunother 2008;31:685-92.
19. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008;14:178-83.
20. Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 2008;8:759-68.
21. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007;39:271-8.
22. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
23. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
24. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:474-81.
25. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER- 2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26: 1789-96.
26. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8.
27. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008;9:482-501.
28. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009;20:685-91.
29. Cardarelli PM, Moldovan-Loomis MC, Preston B, Black A, Passmore D, Chen TH, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res 2009;15:3376-83.
30. Gerdes C, Friess T, Nicolini V, Freytag O, Brünker P, Späni M, et al. GA201, a novel humanized, glycoengineered EGFR antibody with enhanced ADCC and superior preclinical in vivo efficacy as single agent and in combination. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 April 18-22; Denver. Abstract number 5476.
31. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced directand immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402.
32. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010;115: 1204-13.
33. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006;103:4005-10.
34. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
35. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-83.
36. Marrone T, Hu-lowe D, Grazzini M, Yin M, Chen J, Hallin M, , et al. PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 April 14-18; Los Angeles. Abstract number 3992.
37. Mueller BM, Romerdahl CA, Trent JM, Reisfeld RA. Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res 1991;51:2193-8.
38. Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 2006;18: 1115-26.
39. Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. Cancer Res 2008;68:976-80.
40. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996;14:845-51.
41. Tahtis K, Lee FT, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, et al. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther 2003;2:729-37.
42. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21.
43. Leenen PJ, de Bruijn MF, Voerman JS, Campbell PA, van Ewijk W. Markers of mouse macrophage development detected by monoclonal antibodies. J Immunol Methods 1994;174:5-19.
44. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001;61:7846-54.
45. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
46. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008;68:8049-57.
47. Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 2009;100:113-7.
48. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004;10:6248-55.
49. Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, et al. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 2010;12: 822-33.
50. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.